Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Hla-Drb1*01:01, But Not Hla-Drb1:1503 or Hla-Drb1*11, Is Associated With Decreased Inhibitor Risk in Iranian Hemophilia a Patients Publisher Pubmed



Hosseini S1 ; Arabi S2 ; Yari F3 ; Pourfatollah A3 ; Rezaie N4 ; Moazezi S5 ; Aghaie A3
Authors

Source: Transfusion and Apheresis Science Published:2019


Abstract

Background/objective: Hemophilia A is a genetic disorder through which patients suffer from recurrent bleeding. This can be caused by a defect in human plasma coagulation factor VIII. High incidence of FVIII inhibitors in some severe hemophilia A patients after FVIII therapy is a considerable complication. Determination of good predictive factors can improve the safety of this treatment. HLA-II have been shown as a predictive element for inhibitor development. The goal of this study is to determine the association between HLA-DRB1*15:03, HLA-DRB1*11 and HLA-DRB1*01:01 alleles and FVIII inhibitors in severe hemophilia A patients in Iran. Materials/methods: HLA-DRB1 genotyping was performed using Multiplex sequences Specific Primers (PCR-SSP) in two groups of severe hemophilia A patients comprising 51 and 50 individuals with and without FVIII inhibitors respectively. The levels of inhibitor were determined through Nijmegen-modified Bethesda assay. HLA-DRB1 allele frequencies were compared between groups by using multiple logistic regression models. Results: HLA-DRB1*01:01 allele frequency was significantly higher in patients without inhibitor ORadj: 2.7 (95%CI: 1.08, 6.97; P = 0.034). There wasn't any statistically significant difference in HLA-DRB1*11 allele frequency between groups ORadj: 0.7 (95%CI: 0.27, 1.82; P = 0.47). There was no connection between HLA-DRB1*15:03 and inhibitor development ORadj: 0.94 (95%CI: 0.38, 2.35; P = 0.94). Conclusion: An association between HLA-DRB1*01:01 and paucity of FVIII inhibitor showed that this allele has probably a protective effect in severe hemophilia A patients in Iran. Determination of the predictive and protective alleles are beneficial in pre-treatment activities and decrease the risk of unsuccessful therapy with FVIII in each population. © 2019 Elsevier Ltd
Related Docs
View other Related Docs
1. Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor Ii and Factor V With Risk of Inhibitor Development in Patients With Severe Hemophilia A, Cardiovascular and Hematological Disorders - Drug Targets (2019)
2. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
3. Discrepancy Between the Results of One-Stage and Chromogenic Factor Viii:C Assays in Patients With Mild/Moderate Hemophilia A, Blood Coagulation and Fibrinolysis (2020)
Experts (# of related papers)
View all Related Experts
Gholamreza Toogeh (5)
Shaban Alizadeh (2)
Other Related Docs
4. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor, Clinical and Applied Thrombosis/Hemostasis (2016)
5. Genetic Analysis of Non-Severe Hemophilia a Phenotype With a Discrepancy Between One-Stage and Chromogenic Factor Viii Activity Assays, Transfusion and Apheresis Science (2021)
6. Major Histocompatibility Complex (Mhc) Antigens Polymorphism and Alloimmunization Study in Thalassemia Patients With Febrile Non-Hemolytic Transfusion Reaction (Fnhtr), Transfusion Clinique et Biologique (2023)
7. Association of Hla Class Ii Alleles With Hepatitis C Virus Clearance and Persistence in Thalassemia Patients From Iran, Journal of Medical Virology (2015)
8. Increased Expression Level of Human Blood Clotting Factor Viii Using Ns0 Cell Line As a Host Cells, Iranian Journal of Biotechnology (2024)
9. Central Nervous System Bleeding in Pediatric Patients With Factor Xiii Deficiency: A Study on 23 New Cases, Hematology (2015)
10. A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis, Medicine (United States) (2021)
11. Cost-Utility Analysis of Factor Viii Diet Therapies Prepared Using Blood Plasma Vs. Recombinant Technique for Patients With Hemophilia A, DARU# Journal of Pharmaceutical Sciences (2020)
12. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor Vii (Aryoseven™) and Activated Prothrombin Complex Concentrates (Feiba™) to Treat Hemophilia a Patients With Inhibitors in Iran, Iranian Journal of Pharmaceutical Research (2016)
13. Regulatory Mutation Study in Cases With Unsolved Hypochromic Microcytic Anemia and Α-Major Regulatory Element Haplotype Analysis in Iran, Hemoglobin (2021)
14. Health Care Resource Utilization and Cost of Care for Haemophilia a and B Patients in Iran, Transfusion and Apheresis Science (2016)
15. Bleeding Disorder of Unknown Cause: Results From Iranian Study, Transfusion and Apheresis Science (2023)
16. Comprehensive Assessment of Association Between Hla Polymorphisms and Acute Leukemia in Iranian Population, Gene Reports (2020)
17. Acquired Hemophilia a With Intramuscular Hematoma at an Unusual Age: A Case Report, Russian Journal of Pediatric Hematology and Oncology (2022)
18. Diagnosis of Factor Xiii Deficiency, Hematology (2016)
19. Risk and Management of Intracerebral Hemorrhage in Patients With Bleeding Disorders, Seminars in Thrombosis and Hemostasis (2022)
20. Human Leukocyte Antigen (Hla) Class I and Ii Polymorphism in Iranian Healthy Population From Yazd Province, Iranian Journal of Allergy# Asthma and Immunology (2017)